---
schema_version: "secwatch.filing_event.v1"
accession: "0001736730-25-000004"
form_type: "8-K"
ticker: "CAMP"
cik: "0001736730"
company_name: "Camp4 Therapeutics Corp"
filed_at: "2025-03-18T23:59:59+00:00"
generated_at: "2026-05-24T14:03:28.375501+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.3
calibrated_materiality_score: 0.3
confidence: "high"
source: SEC EDGAR
---

# CAMP4 Therapeutics appoints two new directors, expands board to 12 members

## Summary
- Douglas Williams, PhD and Murray Stewart, DM FRCP appointed as Class I and Class II directors, effective 3/17/25.
- Board size increased from 10 to 12 members; Williams also appointed to Audit Committee.
- Each new director granted option to purchase 17,787 shares under 2024 Equity Incentive Plan, vesting monthly over 3 years.
- Standard indemnification agreements entered into; no prior transactions with company exceeding $120,000.

## SEC filing metadata
- accession: 0001736730-25-000004
- form_type: 8-K
- ticker: CAMP
- cik: 0001736730
- company_name: Camp4 Therapeutics Corp
- filed_at: 2025-03-18T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.3
- calibrated_materiality_score: 0.3
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1736730/000173673025000004/0001736730-25-000004-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1736730/000173673025000004/camp-20250312.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001736730-25-000004
- JSON: https://secwatch.observer/filing/0001736730-25-000004.json
- Plain text: https://secwatch.observer/filing/0001736730-25-000004.txt

## Key facts
- Executive change
  Douglas Williams was appointed as Class I Director at Camp4 Therapeutics Corp.
  - Action: appointed
  - Role: Class I Director
  source text: appointed Douglas Williams, PhD as a Class I director
  evidence_url: https://www.sec.gov/Archives/edgar/data/1736730/000173673025000004/0001736730-25-000004-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.